

Insulin secretory responses of a clonal cell line of simian virus 40-transformed B cells

S. J. H. Ashcroft, P. Hammonds and D. E. Harrison*

Nuffield Department of Clinical Biochemistry, John Radcliffe Hospital, Headington, Oxford, UK

Summary. We have evaluated the potential of the clonal insulin-secretory cell line HIT-T15 as a model system for investigating stimulus-secretion coupling in pancreatic B cells. In contrast to other cell lines, HIT cell insulin secretion was consistently stimulated 2- to 3-fold by D-glucose. The maximally effective concentration of glucose was 10 mmol/l; between 2 and 10 mmol/l glucose the increase in insulin release was paralleled by an increased rate of glucose oxidation. The main characteristics of glucose-stimulated insulin release by HIT cells were essentially similar to those of normal islets. Thus, the response was (1) specific for metabolizable sugars (D-mannose and D-glyceraldehyde stimulated insulin release but L-glucose and D-galactose were ineffective); (2) markedly dependent on extracellular Ca^{2+} concentration; (3) potentiated by forskolin, glucagon, acetylcholine and 12-0-tetradecanoyl phorbol 13-acetate; (4) inhibited by adrenaline or somatostatin; (5) showed a biphasic pattern of release in perfusion

experiments, with both phases being potentiated by forskolin. The secretory response of the HIT cells to amino acids was also similar to that of normal islets. Thus, L-leucine and its deamination product 2-ketoisocaproate were effective stimuli, whereas L-isoleucine and L-glutamine were ineffective. Insulin release from HIT cells could also be evoked by the sulphonylureas glibenclamide and tolbutamide and by an increase in concentration of extracellular K^+ to 40 mmol/l. The content of cyclic AMP in HIT cells was increased modestly by glucose but not by an increase in extracellular K^+ . Forskolin elicited a 4-fold increase in cyclic AMP content. We conclude that HIT cells retain the essential features of the insulin secretory response of normal B cells and represent an important tool for further biochemical characterisation of the secretory system.

Key words: Cell line, insulin secretion, HIT cells, B cells.

Biochemical characterisation of normal and pathological B cell function has been restricted by the limited availability and heterogeneity of isolated islets of Langerhans. The recent development of proliferative cell lines [1, 2] that can be grown in tissue culture to yield essentially unlimited amounts of tissue is therefore an important advance.

The clonal insulin-secreting cell line RIN-m5F [1] was developed from a transplantable rat insulinoma [3]. However, although RIN cells respond positively to certain insulin secretagogues, they fail to respond to glucose, the major physiological regulator of insulin secretion [4]. This lack of secretory response to glucose has been attributed to abnormal glucose metabolism in RIN cells [5].

In contrast, by transforming hamster islets with Simian virus 40, Santerre et al. [2] developed a glucose-

responsive cell line (HIT cells). Preliminary characterisation of the HIT cell insulin secretory response also demonstrated stimulation by glucagon and 3-isobutyl-1-methylxanthine (IBMX) and inhibition by somatostatin and dexamethasone [2]. Hill and Boyd [6] have characterised the dynamics of HIT cell insulin release stimulated by glucose, glucose + IBMX and K^+ ; the same authors have recently shown [7] that the release of insulin evoked by glucose or by high K^+ is dependent on the presence of extracellular Ca^{2+} . In addition, Swope and Schonbrunn [8] reported stimulation of basal and glucose-stimulated insulin release in HIT cells by bombesin, a gastrointestinal tetradecapeptide.

Despite these encouraging results, there has been no detailed survey of the secretory properties of HIT cells. Since this is essential for evaluation of the potential of HIT cells as a model for investigating the molecular basis of secretion, we have carried out a comprehensive study of the response of HIT cells to a range of hormones, nutrients and drugs known to modulate insulin

* Present address: CRC Medical Oncology Unit, Southampton General Hospital, Southampton, UK

secretion from normal islets. The interaction between the insulin secretory response to glucose and glucose metabolism and the relationship between intracellular cAMP content and insulin release were also studied.

Materials and methods

Cell culture

HIT cells (clone T15) were generously provided by Dr. A. E. Boyd III (Baylor College of Medicine, Houston, Texas, USA) and Dr. R. F. Santerre (Lilly Research Laboratories, Indianapolis, Ind, USA). For routine culture, 1.2×10^7 cells were seeded in 75 cm² Costar tissue culture flasks (Horwell, London, UK) containing 40 ml RPMI 1640 (Gibco Europe, Paisley, UK) supplemented with glucose (11 mmol/l) penicillin (0.1 mg/ml), streptomycin (0.1 mg/ml) and 10% (v/v) heat-inactivated foetal calf serum (Gibco). Cells were grown at 37°C in a humidified atmosphere of air: CO₂ (95%:5%). Culture medium was replaced every 48 h and cells were passaged at weekly intervals following detachment using Trypsin-EDTA (Gibco).

Insulin secretion: static incubation

HIT cells were passaged 2 days prior to each experiment and seeded at a density of 4×10^5 cells per well in 24-well Costar Multiwell plates. On the day of the experiment, culture medium was aspirated and cells were incubated at 37°C in 1 ml of a modified Krebs bicarbonate medium [9] containing 20 mmol/l Hepes, 5 mg/ml bovine serum albumin (fraction V, Boehringer, Sussex, UK) and additions as listed in the Results section. At timed intervals, 150 µl of incubation medium was removed, centrifuged briefly to sediment any detached cells, diluted in phosphate buffer (40 mmol/l) containing albumin (1 g/l) and merthiolate (6 mmol/l) and stored at -20°C prior to assay. Insulin was measured by radioimmunoassay [10]. The maximum period of incubation was 1 h, during which time the release of insulin was linear.

Insulin secretion: perfusion

The dynamics of HIT-T15 cell insulin secretion were investigated using a perfusion system similar to that described by Hill and Boyd [6]. 4×10^5 cells were seeded into individual wells in a 24-well Costar Multiwell plate containing an 18 mm Thermanox™ tissue culture cover slip (Flow Laboratories, Irvine, Ayrshire, UK). On reaching confluence (72–96 h), coverslips were transferred to 25 mm Swinnox Chambers, Millipore (Harrow, Middlesex, UK) and inserted into a perfusion chamber maintained at 37°C. The flow rate was maintained at 1 ml/min using a peristaltic pump (Anachem, Luton, Bedfordshire, UK). The dead space of the perfusion system is 2 ml, with a corresponding lag time of 2 min. Two-minute fractions were collected for analysis by radioimmunoassay. Swinnox chambers plus cells were preperfused for 1 h without glucose prior to receiving a 30-min stimulation period. Sample collection was started 50-min into the preincubation period.

Glucose oxidation

Aliquots of 5×10^5 HIT cells were incubated for 1 h in a total volume of 50 µl medium containing albumin (5 mg/ml) and D-[U¹⁴C] glucose, specific radioactivity 3.5 dpm/pmol (Amersham International, Amersham, Bucks, UK) at concentrations from 2 to 20 mmol/l. Glucose oxidation rates were determined by measuring ¹⁴CO₂ production as previously described [10].

cAMP content

Metabolism was arrested and cyclic AMP (cAMP) extracted by addition of 0.5 ml hot acetate buffer (50 mmol/l). Samples were sonicated (50 W, 10 s) with a Soniprobe (Dawe Instruments, London, UK) and stored at -20°C prior to assay. cAMP content was determined with a commercial radioimmunoassay kit (Amersham International) using an acetylation protocol.

Reagents

Tolbutamide and glibenclamide were a gift from Smith, Kline and French, Welwyn Garden City, Herts, UK. The phorbol ester 12-*o*-tetradecanoyl-phorbol 13-acetate (TPA) was purchased from PL Biochemicals, Northampton, UK. Forskolin and somatostatin were purchased from Calbiochem, Cambridge, UK. All other reagents were from British Drug House Chemicals, Poole, Dorset, UK or Sigma, Poole, Dorset, UK.

Statistical analysis

In order to combine and compare data from several experiments the following protocol was adopted for insulin secretion measurements. Every Multiwell plate always included 8 control wells containing cells incubated both in the absence (4 wells) and in the presence of 10 mmol/l glucose (4 wells). Release rates for test conditions were then expressed as a percentage of the mean value of the appropriate control rates in the same Multiwell plate and are given throughout as mean ± SEM. For each test condition, duplicate or triplicate experiments were performed with 4 replicates per experiment. The mean absolute control values of insulin release over each series of experiments are also given. The significance of the effects of individual agents on HIT cell insulin release was assessed using Student's *t*-test.

The significance of the dependence on glucose concentration of rates of insulin release was determined using analysis of variance. Data are presented graphically as mean ± 95% confidence limits for the number of observations recorded.

Results

Insulin secretory response to glucose in static incubations

The amount of insulin secreted by HIT-T15 cells in culture varied considerably with time. Table 1 shows rates of insulin release in the absence and presence of glucose (10 mmol/l) between passages 70 and 77. The absolute levels of insulin secreted decreased somewhat with increasing time in culture (concomitant with decreasing insulin content) although glucose consistently doubled the basal secretory rate.

Figure 1 demonstrates the dose-response of glucose-stimulated insulin release from HIT cells, which was shown by analysis of variance to be statistically significant ($p < 0.001$). A threshold glucose concentration of between 2 and 5 mmol/l was required for stimulation of insulin release. Maximal stimulation was observed at 10 mmol/l glucose, with a 2-fold stimulation between 5 and 10 mmol/l glucose. However, from 10–20 mmol/l glucose, the rate of insulin release fell to a level similar to that observed at 5 mmol/l glucose.

The rate of glucose oxidation was also increased between 2 and 10 mmol/l glucose. Glucose oxidation

Table 1. Insulin content and release in HIT cells

Passage number	Insulin content mU/10 ⁶ cells	Insulin release (mU/per well)		Ratio
		Basal	Glucose-stimulated	
70	22.1 ± 1.6	1.39 ± 0.14 (7)	2.41 ± 0.26 (8)	1.74 ± 0.19
71	14.9 ± 0.9	0.32 ± 0.03 (8)	1.07 ± 0.12 (8)	3.31 ± 0.37
72	16.8 ± 1.4	0.39 ± 0.03 (11)	0.82 ± 0.05 (12)	2.12 ± 0.16
73	-	0.64 ± 0.08 (16)	1.38 ± 0.20 (16)	2.16 ± 0.37
75	10.0 ± 0.6	0.25 ± 0.01 (4)	0.43 ± 0.02 (4)	1.74 ± 0.09
76	12.8 ± 0.5	0.16 ± 0.01 (8)	0.32 ± 0.02 (8)	2.05 ± 0.16
77	-	0.15 ± 0.02 (8)	0.40 ± 0.05 (8)	2.74 ± 0.37

HIT cells (4×10^5 – 10^6 cells per well) were incubated at 37 °C for 1 h in HEPES-buffered bicarbonate medium containing albumin (5 g/l) in the absence or presence of glucose (10 mmol/l). The absolute rates of insulin release are given as mean ± SEM for the number of observations in parentheses. The ratio of stimulated to basal insulin release is also given as mean ± SEM and was significantly ($p < 0.001$) greater than 1 at every passage number. For assay of cellular insulin content cells were disrupted by sonication and extracted in 0.1 mol/l Na-borate pH8 containing albumin (2 g/l) and 0.5 mol/l NaCl




Fig. 1. Effect of glucose on HIT cell insulin release. HIT cells (4×10^5 – 10^6) were incubated at 37 °C for 1 h in HEPES-buffered bicarbonate medium containing albumin (5 g/l) in the absence or presence of glucose (2–20 mmol/l). After 1 h, aliquots were removed, centrifuged briefly and insulin released was assayed by radioimmunoassay. Data are presented as mean ± 95% confidence limits ($n = 8$). The dependence of insulin release on glucose concentration was significant by anovar ($p < 0.001$)

rates (pmol/10⁶ cells per h; mean ± SEM, $n = 3$) were 448 ± 9 , 542 ± 12 and 689 ± 8 at 2.5 and 10 mmol/l glucose respectively.

Calcium dependency of basal and glucose-stimulated insulin release

Table 2 shows that glucose-stimulated insulin release from HIT cells was modulated by extracellular Ca^{2+} in a dose-dependent manner. In the absence of Ca^{2+} , stimulation of insulin release by 10 mmol/l glucose was severely inhibited to a level significantly ($p < 0.001$) lower than that from cells incubated at 2.5 mmol/l Ca^{2+} in the absence of glucose. Neither 0.025 nor 0.25 mmol/l Ca^{2+} was sufficient to support glucose-stimulated insulin release. Raising Ca^{2+} to 0.5 mmol/l resulted in a rise in glucose-stimulated insulin release, although this was still significantly ($p < 0.001$) reduced compared to release at normal Ca^{2+} levels (2.5 mmol/l). An increase in Ca^{2+} from 2.5 to 5.0 mmol/l resulted in a significant

($p < 0.01$) enhancement of glucose-stimulated insulin release.

Initiation of insulin release

The ability of various agents to initiate insulin release from HIT cells in the absence of other additions is summarised in Table 3.

In cells incubated with 10 mmol/l glucose the rate of insulin release was significantly greater ($p < 0.001$) than that seen in the absence of additions (2.5-fold) or in the presence of 2 mmol/l glucose (1.75-fold). The addition of either L-glucose (10 mmol/l) or D-galactose (10 mmol/l) failed to cause any enhancement of insulin release above that seen in the absence of additions. However, both D-mannose (10 mmol/l) and D-glyceraldehyde (10 mmol/l) elicited insulin release to an extent not significantly different from that seen in the presence of 10 mmol/l glucose.

Stimulation of insulin release was also found in the presence of leucine (20 mmol/l) or 2-ketoisocaproate acid (10 mmol/l). However, both glutamine (20 mmol/l) and isoleucine (20 mmol/l) proved ineffective.

The lowered insulin secretory rate seen in the absence of added nutrient was not attributable simply to an impairment of energy metabolism, since several non-nutrient secretagogues proved effective stimuli in the absence of glucose. Thus, raising the extracellular K^+ level from 4.75 to 40 mmol/l provoked a marked stimulation of insulin release to a greater extent than seen with 10 mmol/l glucose. The adenylate cyclase activator forskolin (10 μ mol/l) was also a potent initiator of insulin release in the absence of glucose. Finally, the hypoglycaemic sulphonylureas tolbutamide (1 mmol/l) and glibenclamide (20 μ g/ml) caused a marked stimulation of insulin release to levels in excess of that elicited by 10 mmol/l glucose.

Modulation of glucose-stimulated insulin release

Table 4 shows the effect of various agents on insulin release in the presence of 10 mmol/l glucose. Forskolin

Table 2. Dependence of insulin secretion from HIT cells on extracellular Ca^{2+}

Line	Glucose (mmol/l)	Ca^{2+} (mmol/l)	Insulin release (%)
1	10	2.5	100
2	10	0	30 ± 2 (20) ^a
3	10	0.025	37 ± 6 (8) ^a
4	10	0.25	30 ± 4 (8) ^a
5	10	0.5	53 ± 10 (8) ^{a, d}
6	10	1	64 ± 6 (12) ^{a, d}
7	10	5	161 ± 17 (7) ^b
8	0	2.5	47 ± 3 (24) ^b
9	0	0	24 ± 2 (8) ^c

HIT cells were incubated in Multiwells in 1 ml HEPES-buffered bicarbonate medium containing albumin (5 g/l) and glucose and Ca^{2+} at the concentrations given. Medium containing zero Ca^{2+} also contained 10 $\mu\text{mol/l}$ EGTA. After 1 h a sample of medium was briefly centrifuged to sediment any free floating cells and the insulin in the supernatant was measured by radioimmunoassay. In order to combine data from the complete series of experiments, every Multiwell plate included cells incubated under control conditions (10 mmol/l glucose and 2.5 mmol/l Ca^{2+}); release rates for each test condition were then calculated as a percentage of the mean release rate for the control wells in the same Multiwell plate, i. e. for cells of identical passage number and seeding density. Results are given as mean ± SEM for the number of observations in parentheses. Over these experiments the mean absolute value of insulin release in control wells was 1.46 ± 0.21 mU/well ($n = 23$). Statistical significances of the observed differences in insulin release are: ^a $p < 0.001$ vs 1; ^b $p < 0.01$ vs 1; ^c $p < 0.001$ vs 8; ^d $p < 0.05$ vs 2

Table 3. Effects of agents on insulin release by HIT cells

Line	Addition	Concentration	Insulin release (%)
1	D-Glucose	10 mmol/l	100
2	None	-	40 ± 3 (60) ^a
3	D-Glucose	2 mmol/l	57 ± 7 (12) ^a
4	D-Mannose	10 mmol/l	118 ± 13 (8)
5	L-Glucose	10 mmol/l	29 ± 6 (8) ^a
6	D-galactose	10 mmol/l	40 ± 4 (8) ^a
7	D-glyceraldehyde	10 mmol/l	102 ± 14 (8)
8	L-leucine	20 mmol/l	113 ± 15 (8)
9	L-isoleucine	20 mmol/l	50 ± 7 (8) ^a
10	2-ketoisocaproate	10 mmol/l	81 ± 13 (8)
11	L-glutamine	20 mmol/l	52 ± 10 (8) ^a
12	K^+	40 mmol/l	268 ± 42 (12) ^b
13	Forskolin	10 mmol/l	151 ± 16 (12) ^b
14	Tolbutamide	1 mmol/l	186 ± 40 (8) ^b
15	Glibenclamide	20 $\mu\text{g/ml}$	207 ± 38 (8) ^b
16	Adrenaline	10 mmol/l	30 ± 5 (8) ^a

HIT cells were incubated in Multiwells for 60 min in 1 ml HEPES-buffered bicarbonate medium containing albumin (5 g/l) and the additions stated. Insulin released into the medium was measured by radioimmunoassay. Every Multiwell plate included cells incubated with 10 mmol/l glucose. In order to combine data from the complete series of experiments, release rates for each condition were expressed as a percentage of the mean release rate in cells exposed to 10 mmol/l glucose in the same Multiwell plate. Results are given as mean ± SEM for the number of observations given in parentheses. The mean absolute values of insulin release (mU/well) from the control wells in the presence of 10 mmol/l glucose for this series of experiments was 1.24 ± 0.12 ($n = 52$). Statistical significances of the observed differences in release rate under test conditions from that in the presence of 10 mmol/l glucose are: ^asignificantly ($p < 0.001$) less; ^bsignificantly ($p < 0.01$) greater

Table 4. Effects of agents on glucose-stimulated insulin release from HIT cells

Line	Glucose (mmol/l)	Other additions	Concentration	Insulin release (%)
1	10	None	-	100
2	10	Forskolin	10 $\mu\text{mol/l}$	386 ± 35 (8) ^a
3	10	Acetylcholine	10 $\mu\text{mol/l}$	125 ± 3 (6) ^a
4	10	TPA	0.1 $\mu\text{mol/l}$	400 ± 87 (8) ^b
5	10	Glucagon	5 $\mu\text{g/ml}$	173 ± 16 (7) ^a
6	10	Adrenaline	5 $\mu\text{mol/l}$	53 ± 6 (8) ^a
7	10	Somatostatin	5 $\mu\text{g/ml}$	37 ± 3 (8) ^a

HIT cells were incubated with the additions shown as described in the legend to Table 2. Insulin release measured by radioimmunoassay is expressed as a percentage of the mean rate observed with 10 mmol/l glucose in the same Multiwell plate. Data are given as mean ± SEM for the number of observations shown. For this series of experiments the mean absolute rate of insulin release in control wells with 10 mmol/l glucose was 1.63 ± 0.145 mU/well ($n = 23$); the mean rate of insulin release for cells incubated without additions was 40 ± 3 percent ($n = 24$) of the rate found in the presence of 10 mmol/l glucose. Significance of the differences between test and control (10 mmol/l glucose) are: ^a $p < 0.001$; ^b $p < 0.01$

Table 5. Effect of secretagogues on intracellular cAMP levels

Line	[D-Glucose] (mmol/l)	Other additions	[cAMP] (pmol/10 ⁶ cells)
1	-	-	6.4 ± 0.5
2	-	Forskolin (10 $\mu\text{mol/l}$)	24.4 ± 4.6 ^a
3	10	-	9.8 ± 0.6 ^b
4	10	Forskolin (10 $\mu\text{mol/l}$)	26.1 ± 4.7 ^c
5	-	K^+ (40 mmol/l)	5.3 ± 0.4

After incubation for 1 h under the conditions shown, HIT cells were extracted and cyclic AMP content was determined by radioimmunoassay. Data are given as mean ± SEM for four observations. Significance of the observed differences are: ^a $p < 0.05$ vs 1; ^b $p < 0.01$ vs 1; ^c $p < 0.05$ vs 3

(10 $\mu\text{mol/l}$) potentiated glucose-stimulated insulin release almost 4-fold. Glucose-stimulated insulin release was also potentiated 4-fold by the phorbol ester TPA, by 10 $\mu\text{mol/l}$ acetylcholine (1.3-fold) and by 5 $\mu\text{g/ml}$ glucagon (1.7-fold). In contrast both adrenaline (5 $\mu\text{mol/l}$) and somatostatin (5 $\mu\text{g/ml}$) caused marked inhibition of glucose-stimulated insulin release.

Effect of various secretagogues on intracellular cAMP levels

Table 5 shows the effect of various secretagogues on intracellular cAMP levels.

Raising the glucose concentration to 10 mmol/l caused a significant ($p < 0.01$) rise in cAMP from 6.4 ± 0.5 to 9.8 ± 0.6 pmol/10⁶ cells, concomitant with a 2-fold stimulation of insulin release (Table 1). Forskolin (10 $\mu\text{mol/l}$) induced a marked elevation of cAMP levels both in the absence of glucose and also at 10 mmol/l glucose. In contrast, the stimulation of insulin release by increased extracellular K^+ (Table 3) did not significantly alter intracellular cAMP levels.




Fig. 2. Effect of glucose and glucose plus forskolin on HIT cell insulin secretory dynamics. HIT cells (4×10^5 – 10^6) were grown on coverslips and transferred to perfusion chambers. Cells were first perfused for a period of 60 min in basal medium with collection of fractions for insulin assay during the last 10 min. The perfusion medium was then changed (first arrow) for one containing glucose (10 mmol/l) in the absence (A) or presence (B) of forskolin (10 μ mol/l). After a 30-min stimulation period (second arrow) cells were again perfused with basal medium. The flow rate was 1 ml/min, lag time 2 min. The data shown are representative of three similar experiments

Effect of glucose and glucose plus forskolin on the dynamics of HIT cell insulin release

Figure 2 demonstrates the dynamics of glucose-stimulated insulin release and its potentiation by forskolin.

Preincubation for 1 h without glucose resulted in a steady baseline which was maintained in the absence of stimulation (data not shown). Stimulation by glucose (10 mmol/l) induced a biphasic secretory response. Taking into account a lag time of 2 min for the perfusion system, a first-phase peak insulin secretory rate of 24.5 μ U/min was achieved 6 min after stimulation. During the next four min, the rate of secretion decreased rapidly but was followed by a second phase of secretion characterised by a lower insulin secretory rate (approximately 15 μ U/min) that was maintained (but did not continue to increase) for the duration of the glucose challenge. On removal of glucose, the insulin secretory rate returned to basal levels.

A combination of glucose (10 mmol/l) and forskolin (10 μ mol/l) provoked a 4-fold potentiation of glucose-stimulated insulin release in HIT cells in static incubations. Figure 2 shows that this was characterised by potentiation of both phases of insulin secretion. Again, removal of the stimulus was characterised by a rapid return to basal secretion levels.

The data shown are representative of three similar experiments.

Discussion

The development of proliferative B-cell lines that retain the functional characteristics of normal islets would represent a significant advance in the study of the molecular basis of insulin secretion.

Previous studies [2, 6–8] have suggested a considerable potential for HIT cells as a model system for investigating stimulus-secretion coupling in pancreatic B cells. The aim of the present investigation was to evaluate this potential by comprehensively surveying the secretory response of HIT cells to a range of nutrients, hormones and drugs known to modulate insulin release in normal islets.

In static incubations, 2- to 3-fold stimulation of HIT cell insulin release by glucose was consistently observed with a dose response curve similar to that for HIT cell glucose oxidation. The magnitude of the secretory response to glucose was lower than that of islets of Langerhans but was similar to that reported for dispersed islet cells [12]. The specificity of the secretory response to nutrients was essentially similar to that of normal islets; thus mannose, glyceraldehyde, leucine and 2-ketosocaproate elicited stimulation of insulin release whereas L-glucose, galactose, isoleucine and glutamine were ineffective. In contrast to Hill and Boyd [6, 7], who demonstrated a monophasic insulin response to glucose, we observed a biphasic secretory response to glucose in HIT cells that is typical of that found in normal islets.

Stimulation of insulin release by glucose depends on the presence of extracellular calcium ions. Glucose failed to stimulate insulin secretion from HIT cells when extracellular Ca^{2+} was less than 0.5 mmol/l.

Using a different protocol, in which HIT cells were preincubated for 1 h in the absence of glucose and in the presence of varying Ca^{2+} concentrations and then stimulated with 19.7 mmol/l glucose at the same Ca^{2+} concentration, Boyd et al. [7] also demonstrated a similar dependency on the extracellular Ca^{2+} concentration of glucose-stimulated insulin release from HIT cells. Glucose-stimulated insulin secretion increased over the range 0.5 to 2.5 mmol/l Ca^{2+} but glucose did not stimu-

late insulin release above basal rates (equivalent Ca^{2+} concentrations and no glucose) when glucose was added to zero or 0.1 mmol/l Ca^{2+} [7]. We find, in addition, that an elevation of extracellular Ca^{2+} from the normal 2.5 to 5 mmol/l caused an increased rate of glucose-induced insulin release. These data are consistent with the calcium dependency of islets, which show a threshold requirement of 0.1 mmol/l and maximum response between 5 and 10 mmol/l Ca^{2+} [13]. B-cell insulin release may be triggered by increasing the cytoplasmic Ca^{2+} concentration [14]. One method of achieving this is to depolarise cells by increasing the extracellular potassium concentration, which causes influx of calcium through voltage-sensitive calcium channels. Raising K^+ from 4.75 to 40 mmol/l resulted in a 6-fold stimulation of basal HIT cell insulin release in static incubations. Hill and Boyd [6] demonstrated a monophasic secretory response to K^+ in a perfusion system. Sulphonylureas with insulin-releasing effects also promote the entry of Ca^{2+} into B cells [15]. HIT cell insulin release was markedly stimulated by tolbutamide and glibenclamide. These findings suggest that the interaction between calcium and insulin release in HIT cells resembles that of normal islets.

Moreover, the ability of such non-nutrient secretagogues to initiate insulin release in the absence of glucose suggests that the lower insulin release seen in HIT cells incubated without additions is not attributable solely to a lack of exogenous nutrient.

Glucose-stimulated insulin release from HIT cells was inhibited by somatostatin or adrenaline as for islets of Langerhans [16]. Marked potentiation of glucose-stimulated insulin release was elicited by forskolin or glucagon, which may act by activation of cyclic AMP-dependent protein kinase [9]; by acetylcholine which may enhance turnover of inositol phospholipids [17]; and by a phorbol ester which has been shown to activate Ca^{2+} -phospholipid-dependent protein kinase in B-cells [18] as in other cells [19]. These data suggest that HIT cells possess the full range of pathways for modulating insulin secretion previously demonstrated in islets of Langerhans.

The potent enhancement of insulin secretion seen in the combined presence of glucose and forskolin was further studied. In perfusion experiments the effect of forskolin was shown to involve potentiation of both phases of glucose-stimulated insulin release, and forskolin was shown to augment markedly the level of cyclic AMP in HIT cells. Elevation of cyclic AMP was not a necessary condition for insulin release since stimulation of insulin release by high K^+ concentration did not lead to any increase in HIT cell cyclic AMP. It is noteworthy that, as in islets of Langerhans [20], glucose itself, in the absence of forskolin, was able to elevate HIT cell cyclic AMP. When cyclic AMP was increased by forskolin, however, the simultaneous presence of glucose resulted in no detectable further increase in cyclic AMP but caused a 2-fold increase in insulin secre-

tion (compare Table 3, line 13 with Table 4, line 2). Moreover, although forskolin was able to initiate insulin release in the absence of glucose, the magnitude of this response was only 50% greater than that of glucose despite the fact that cyclic AMP was increased 4-fold by forskolin but only 50% by glucose. These findings suggest that in HIT cells, as in islets of Langerhans [20], cyclic AMP plays a predominantly modulatory rather than initiatory role in the regulation of insulin release.

We conclude from these studies that HIT cells possess an insulin secretory response that retains the essential features of the normal differentiated B cell. The HIT cell line should therefore serve as an important source of material for further elucidation of the molecular mechanisms regulating insulin secretion.

Acknowledgements. These studies were supported by grants from the British Diabetic Association and the Medical Research Council. We thank Ms. M. Milewski, J. Chatterjee and H. Reed for expert technical assistance, Ms. G. Bates for typing this manuscript and Drs. A. E. Boyd III and R. F. Santerre for providing samples of HIT cells.

References

1. Gazdar AF, Chick WL, Oie HK, Sims HL, King DL, Weir GC, Lauris V (1980) Continuous, clonal insulin- and somatostatin-secreting cell lines established from a transplantable rat islet cell tumor. *Proc Natl Acad Sci USA* 77: 3519-3523
2. Santerre RF, Cook RA, Crisel RMD, Sharp JD, Schmidt RJ, Williams DC, Wilson CP (1981) Insulin synthesis in a clonal cell line of Simian virus 40-transformed hamster pancreatic beta cells. *Proc Natl Acad Sci USA* 78: 4339-4343
3. Chick WL, Warren S, Chute RN, Like AA, Lauris V, Kitchen KC (1977) A transplantable insulinoma in the rat. *Proc Natl Acad Sci USA* 74: 628-632
4. Praz GA, Halban PA, Wollheim CB, Blondel B, Strauss AJ, Renold AE (1983) Regulation of immunoreactive-insulin release from a rat cell line (RINm5F). *Biochem J* 210: 345-352
5. Halban PA, Praz GA, Wollheim CB (1983) Abnormal glucose metabolism accompanies failure of glucose to stimulate insulin release from a rat pancreatic cell line (RINm5F). *Biochem J* 212: 439-443
6. Hill RS, Boyd III AE (1985) Perfusion of a clonal cell line of Simian virus 40-transformed beta cells. Insulin secretory dynamics in response to glucose, 3-isobutylmethylxanthine and potassium. *Diabetes* 34: 115-120
7. Boyd III AE, Hill RS, Oberwetter AM, Berg M (1986) Calcium dependency and free calcium concentrations during insulin secretion in a hamster beta cell line. *J Clin Invest* 77: 774-781
8. Swope SL, Schonbrunn A (1984) Bombesin stimulates insulin secretion by a pancreatic islet cell line. *Proc Natl Acad Sci USA* 81: 1822-1866
9. Christie MR, Ashcroft SJH (1985) Substrates for cyclic AMP-dependent protein kinase in islets of Langerhans. Studies with forskolin and catalytic subunit. *Biochem J* 227: 727-736
10. Ashcroft SJH, Crossley JR (1975) Effects of glucose, N-acetylglucosamine, glyceraldehyde and other sugars on insulin release in vivo. *Diabetologia* 11: 274-279
11. Ashcroft SJH, Hedekov CJ, Randle PJ (1970) Glucose metabolism in mouse pancreatic islets. *Biochem J* 118: 143-154
12. Pipeleers D (1984) Islet cell interactions with pancreatic B-cells. *Experientia* 40: 1114-1126
13. Hellman B (1975) The significance of calcium for glucose stimulation of insulin release. *Endocrinology* 97: 392-398

14. Wollheim CB, Sharp GWA (1981) Regulation of insulin release by calcium. *Physiol Rev* 61: 914-973
15. Gylfe E, Hellman B, Sehlin J, Taljedal IB (1984) Interaction of sulphonylureas with the pancreatic B-cell. *Experientia* 40: 1126-1134
16. Smith PH, Porte JRD, Robertson RP (1979) Neural regulation of the endocrine pancreas. In: Pierluzzi J (ed) *Endocrine pancreas and diabetes*. Excerpta Medica, Amsterdam, pp 64-95
17. Best L, Dunlop M, Malaisse WJ (1984) Phospholipid metabolism in pancreatic islets. *Experientia* 40: 1075-1084
18. Harrison DE, Ashcroft SJH, Christie MR, Lord JM (1984) Protein phosphorylation in the pancreatic B-cell. *Experientia* 40: 1075-1084
19. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y (1982) Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumour-promoting phorbol esters. *J Biol Chem* 257: 7847-7851
20. Christie MR, Ashcroft SJH (1984) Cyclic AMP-dependent protein phosphorylation and insulin secretion in intact islets of Langerhans. *Biochem J* 218: 87-99

Received: 14 March 1986
and in revised form: 28 August 1986

Dr. S.J.H. Ashcroft,
Nuffield Department of Clinical Biochemistry
John Radcliffe Hospital,
Headington,
Oxford OX3 9DU
UK